Do you want to learn more about your cancer risk? In this workshop, Dr. Melissa Frey and Arielle Nelson will discuss the importance of genetic testing for hereditary cancer syndromes and provide resources for individuals interested in pursuing genetic testing. If you attend, you’ll also receive their digital genetic cancer risk assessment.
Approximately 20% of patients with ovarian cancer carry an underlying pathogenic gene variant (PGV) in a cancer associated gene, which is most commonly in genes associated with hereditary breast and ovarian cancer such as BRCA1 and BRCA2. Given the high prevalence of genetic variants, American Society of Clinical Oncology, the U.S. Preventive Services Task Force, the National Comprehensive Cancer Network, the Society of Gynecologic Oncology, and the American College of Obstetricians and Gynecologists all recommend universal genetic counseling and testing for women diagnosed with epithelial ovarian cancer.
However, despite this recommendation and more than two decades since the discovery of the genetic predisposition to ovarian cancer, the promise of genomics as a tool for cancer prevention has yet to be fully realized.
Dr. Melissa Frey is an Associate Professor of Obstetrics and Gynecology in the Division of Gynecologic Oncology and the Director of the Genetics and Personalized Cancer Prevention Program at Weill Cornell Medicine. Arielle Nelson is a Nurse Practitioner at the Genetics and Personalized Cancer Prevention Program.
This is a FREE and VIRTUAL workshop.
